🇺🇸 AZD 1222 in United States

835 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 835

Most-reported reactions

1. Drug Ineffective — 93 reports (11.14%)
2. Off Label Use — 92 reports (11.02%)
3. Fatigue — 91 reports (10.9%)
4. Covid-19 — 90 reports (10.78%)
5. Condition Aggravated — 79 reports (9.46%)
6. Inappropriate Schedule Of Product Administration — 79 reports (9.46%)
7. Colitis Ulcerative — 78 reports (9.34%)
8. Headache — 78 reports (9.34%)
9. Pain — 78 reports (9.34%)
10. Frequent Bowel Movements — 77 reports (9.22%)

Source database →

Frequently asked questions

Is AZD 1222 approved in United States?

AZD 1222 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for AZD 1222 in United States?

University Medicine Greifswald is the originator. The local marketing authorisation holder may differ — check the official source linked above.